WeightWatchers files for bankruptcy — These GLP-1 firms want to help you meet your goals
As GLP-1 firms continue to bulk up, WeightWatchers (WW) is stepping off the scale.
The points-system-based weight loss program filed for bankruptcy on May 6, with its premarket value plummeting 52% by Wednesday morning.
A growing debt burden forced the company to scale back operations, but current members were assured they wouldn't be affected by the filing. A reorganization plan is expected within 40 days, according to a statement released Tuesday.
Advertisement
'As the conversation around weight shifts toward long-term health, our commitment to delivering the most trusted, science-backed, and holistic solutions — grounded in community support and lasting results — has never been stronger, or more important,' said Tara Comonte, Chief Executive Officer of WW.
Comonte suggested that the filing was supported by lenders, who are committed to helping the company shed its $1.15 billion debt, appeal to new customers, and innovate in the rapidly evolving weight management landscape — a space that is currently swamped with competitive GLP-1 solutions.
WeightWatchers has struggled to maintain subscriptions as people turn to popular medications like Ozempic, Mounjaro, and Wegovy.
Originally used to treat diabetes, GLP-1s have become an attractive option for those looking to suppress hunger and shed pounds fast.
Advertisement
The company found some relief after adding GLP-1 obesity treatment offerings in 2023, but still hasn't strayed from the more traditional approach to weight loss, focusing on food intake and behavioral changes. On Tuesday's call, Comonte acknowledged the surge of GLP-1 usage, but added that they are 'a medication, not a miracle.'
According to a recent Kaiser Family Foundation poll, roughly 6% of U.S. adults are currently taking GLP-1 for weight loss, and the effects are impressive. A 2022 study found that people who received weekly semaglutide injections lost an average of about 15 pounds after three months.
Over the last couple of years, some insurance providers have announced they would no longer offer coverage for weight-loss medications like Ozempic. In response, some have begun turning to telehealth companies like Ro, G-Plans Direct, and Remedy Meds — all of which offer virtual prescriptions for different weight-loss drugs, as well as other health services.
It's a tough time to compete with new weight-loss drugs; different payment plans are available, treatments are more accessible for people without insurance, and telehealth companies are offering easier paths towards getting a prescription. Still, the GLP-1 landscape can be difficult to navigate.
Advertisement
Here's the skinny on the telehealth companies worth considering.
Looking for a headline-worthy haul? Keep shopping Post Wanted.
This article was written by Miska Salemann, New York Post Commerce Writer/Reporter. As a health-forward member of Gen Z, Miska seeks out experts to weigh in on the benefits, safety and designs of both trending and tried-and-true fitness equipment, workout clothing, dietary supplements and more. Taking matters into her own hands, Miska intrepidly tests wellness products, ranging from Bryan Johnson's Blueprint Longevity Mix to home gym elliptical machines to Jennifer Aniston's favorite workout platform – often with her adorable one-year old daughter by her side. Before joining The Post, Miska covered lifestyle and consumer topics for the U.S. Sun and The Cannon Beach Gazette.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
6 hours ago
- The Hill
The FDA must crack down on dangerous knockoff weight-loss drugs
For the first time, there is real hope in the fight against obesity. New data from the Centers for Disease Control and Prevention's National Center for Health Statistics shows that adult obesity rates in the U.S. may finally be flatlining after annual increases since at least 2011. Obesity has long been understood to be the second leading cause of preventable death in America. Neither negative cultural attitudes about weight nor government messaging campaigns about diets have helped curb it. Yet like most insurmountable problems, we are innovating our way out of it. Experts believe a significant part of recent progress is due to powerful new medications such as Ozempic and Mounjaro, known as GLP-1 drugs. But just as these drugs are changing lives, a dangerous shadow market is growing alongside them. Compounded versions, which are copies of the original drugs made in smaller pharmacies, are flooding websites, med spas and clinics. These versions are often cheaper and easier to get than the real thing. They are also frequently untested, poorly regulated and, in many cases, illegal. The FDA has received more than 500 reports of serious side effects tied to compounded semaglutide and tirzepatide, the active ingredients in Ozempic and Mounjaro. Some patients have landed in the hospital after taking the wrong dose. That is not surprising when you consider that many of these vials come without proper labels or instructions. In 2023 alone, poison control centers received nearly 3,000 semaglutide-related calls, a huge jump from previous years. Many of those cases involved compounded or mislabeled versions of the medication. There are also serious concerns about what is actually in these products. The FDA has warned that some pharmacies are using different chemical forms of semaglutide, called salt forms, that are not approved for use and may not be safe. In April 2025, the agency seized counterfeit Ozempic from the U.S. supply chain after discovering that some vials contained the wrong ingredients or were contaminated with dangerous bacteria. These are not technical violations. They are real risks to people's health. During earlier shortages, compounding was allowed under special circumstances. But those shortages have ended, and the FDA has ordered most pharmacies to stop making these versions. Despite that, many continue to operate in legal gray zones or offer these drugs online. The harm does not stop with safety concerns. This trend also threatens future breakthroughs in obesity care. Companies like Novo Nordisk and Eli Lilly spent years and billions of dollars to develop these treatments. Now, they and others are working on new and even more effective drugs. When unapproved copies flood the market, it becomes harder to fund innovation. If investors cannot count on fair returns, the next generation of such medications may not make it out of the lab. Perhaps the biggest risk is to public trust. When someone has a bad experience with a fake or contaminated version, they may begin to doubt all weight loss innovations. That fear can ripple through the health system, making insurers and doctors more hesitant to support treatments that are helping with the genuine public health emergency of obesity. None of this means that compounding should disappear. It has a place when patients have specific medical needs that cannot be met by the approved versions, such as allergies or special dosing requirements. But what is happening now is not about rare exceptions. The FDA should continue cracking down on compounders that use unapproved ingredients or sell mislabeled products disguised as 'research chemicals.' At the same time, insurers and lawmakers need to make the real thing more affordable by removing middlemen such as pharmacy benefit managers. No one should have to choose between risking their health and going broke. We are finally making progress against a disease that affects nearly half the country and has stumped policymakers and advocates for decades. But progress is fragile. Unregulated versions of GLP-1s cannot be allowed to dominate the market. We risk undoing the progress reported by the CDC in the fight against obesity, and if we get this right, the trend could be reversed. That means longer lives for more people, lived in dignity and to the fullest.
Yahoo
15 hours ago
- Yahoo
1&1's (ETR:1U1) Returns On Capital Not Reflecting Well On The Business
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in conjunction with a growing amount of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. Although, when we looked at 1&1 (ETR:1U1), it didn't seem to tick all of these boxes. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Understanding Return On Capital Employed (ROCE) For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. The formula for this calculation on 1&1 is: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.07 = €546m ÷ (€8.4b - €680m) (Based on the trailing twelve months to March 2025). Therefore, 1&1 has an ROCE of 7.0%. In absolute terms, that's a low return and it also under-performs the Wireless Telecom industry average of 9.0%. Check out our latest analysis for 1&1 Above you can see how the current ROCE for 1&1 compares to its prior returns on capital, but there's only so much you can tell from the past. If you're interested, you can view the analysts predictions in our free analyst report for 1&1 . The Trend Of ROCE On the surface, the trend of ROCE at 1&1 doesn't inspire confidence. To be more specific, ROCE has fallen from 13% over the last five years. Meanwhile, the business is utilizing more capital but this hasn't moved the needle much in terms of sales in the past 12 months, so this could reflect longer term investments. It's worth keeping an eye on the company's earnings from here on to see if these investments do end up contributing to the bottom line. The Bottom Line On 1&1's ROCE To conclude, we've found that 1&1 is reinvesting in the business, but returns have been falling. Since the stock has declined 16% over the last five years, investors may not be too optimistic on this trend improving either. All in all, the inherent trends aren't typical of multi-baggers, so if that's what you're after, we think you might have more luck elsewhere. One more thing to note, we've identified 2 warning signs with 1&1 and understanding these should be part of your investment process. While 1&1 isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 hours ago
- Yahoo
1&1's (ETR:1U1) Returns On Capital Not Reflecting Well On The Business
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in conjunction with a growing amount of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. Although, when we looked at 1&1 (ETR:1U1), it didn't seem to tick all of these boxes. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Understanding Return On Capital Employed (ROCE) For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. The formula for this calculation on 1&1 is: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.07 = €546m ÷ (€8.4b - €680m) (Based on the trailing twelve months to March 2025). Therefore, 1&1 has an ROCE of 7.0%. In absolute terms, that's a low return and it also under-performs the Wireless Telecom industry average of 9.0%. Check out our latest analysis for 1&1 Above you can see how the current ROCE for 1&1 compares to its prior returns on capital, but there's only so much you can tell from the past. If you're interested, you can view the analysts predictions in our free analyst report for 1&1 . The Trend Of ROCE On the surface, the trend of ROCE at 1&1 doesn't inspire confidence. To be more specific, ROCE has fallen from 13% over the last five years. Meanwhile, the business is utilizing more capital but this hasn't moved the needle much in terms of sales in the past 12 months, so this could reflect longer term investments. It's worth keeping an eye on the company's earnings from here on to see if these investments do end up contributing to the bottom line. The Bottom Line On 1&1's ROCE To conclude, we've found that 1&1 is reinvesting in the business, but returns have been falling. Since the stock has declined 16% over the last five years, investors may not be too optimistic on this trend improving either. All in all, the inherent trends aren't typical of multi-baggers, so if that's what you're after, we think you might have more luck elsewhere. One more thing to note, we've identified 2 warning signs with 1&1 and understanding these should be part of your investment process. While 1&1 isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
